Spero Therapeutics receives grant from National Institutes of Health to explore novel treatment combinations for TB

CAMBRIDGE, Mass., May 4, 2017—Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today announced that it has received a grant from the National Institutes of Health (NIH) to conduct additional preclinical studies of SPR720, the Company’s novel oral bacterial gyrase inhibitor, for the treatment of tuberculosis (TB). The non-dilutive grant of $564,718 is part of the NIH’s Small Business Innovation Research (SBIR) program (Grant Number: 1R44AI131749-01).